Singapore’s National Platform for
Diagnostics Development
DxD Hub is an end-to-end productisation partner dedicated to transforming the MedTech landscape in Singapore, through innovative solutions from both local and regional partners. We expedite diagnostics and digital health product development by enabling validation, registration, and deployment of solutions that improve patient care and save lives.
We are a high-throughput productisation platform, whose strengths consists of the cross-cutting, multidisciplinary product development specialists from all walks of life. These specialists work with both public and private partners in different areas across the product development life cycle, including: product development, pilot production, quality assurance, building business cases, obtaining regulatory clearance, gaining clinical adoption, and transferring customised manufacturing processes and technologies to companies for manufacturing scale-ups.Ìý
The Journey So Far
NOV 2014
DxD HubÌýwas launched by then-Second Minister for Trade and Industry, Mr S Iswaran.Ìý
Jan 2015
DxD Hub attainedÌýISO 13485ÌýIVD design and development certification.
May 2017
³¢²¹±ð²Ô²Ô±ð³¦Â®Ìý(co-developed with HistoIndex and SGH) is the world’s first stain-free digital pathology imaging system approved for clinical diagnosis of liver diseases.Ìý
2019
DxD Hub’sÌýClinical Laboratory (ClinLab)Ìýis established to pilot the deployment of innovative tests developed by DxD Hub, or its strategic partners in òòò½Íøand the region.Ìý
May 2019
GASTROCLEARâ„¢Ìý(co-developed with MiRXES, SGCC, NUH, and TTSH), approved as a Class 3 IVD, is the world’s first miRNA blood test for early detection of gastric cancer.Ìý
Ìý
Jul 2019
Tissue PD-L1 Triplexâ„¢Ìý(co-developed with Lucence, IMCB and SGH) is the first immunohistochemistry tissue
test for three PD-L1 markers.
Feb 2020
Fortitude 2.0Ìý(co-developed and launched with EDDC, BII, TTSH and licensed to MiRXES) is the first test kit for COVID-19 management in Singapore.
May 2020
´¡³§³§±«¸é·¡Â®Ìý(co-developed with MP Biomedicals and NUH) is an antibody detection test kit for COVID-19 virus.
May 2020
³¦±Ê²¹²õ²õâ„¢Ìý(co-developed with Duke-NUS and GenScript) is a novel surrogate test for COVID-19 viral neutralisation antibodies.
May 2020
Respiree MonitorÌý(co-developed with Respiree and SBIC) is a wearable device that can predict worsening conditions in COVID-19 patients.
Jun 2020
RESOLUTE 2.0Ìý(co-developed with DSO) is a one-step RT-PCR test for COVID-19 eliminating the need for an additional RNA extraction kit.
Jun 2020
RAVEÌý(co-developed with AMT, ARTC, and SIMTech) was developed as an automated lab system that runs RESOLUTE 2.0 in half the time.
26th Oct 2021
The RESOLUTE 2.0 team is awarded theÌýDefence Technology PrizeÌýby the Ministry of Defence, in recognition of their contributions towards enhancing Singapore’s defence capabilities.
14th Sept 2021
°Õ¾±²õ²õ³Ü±ð500â„¢Ìýis made commercially available, and is showcased at both local and regional conferences such as the Frontier in Cancer Science 2021 in Singapore, and the United States & Canadian Academy of Pathology (USCAP) 2022 Annual Meeting.
Mar 2022Ìý
PREPARE IDDx CO-OP
4th Apr 2022
The National Research Foundation approves theÌýDigital Health Accelerator Funding Initiative.Ìý
May 2022
DxD Hub’s ClinLab receivesÌýCAP Accreditation.
6th July 2022
The RESOLUTE 2.0 team is awarded theÌýExemplary Innovator AwardÌýat the 2022 Public Sector Transformation COVID-19 Awards 2022.
April 2023
DxD Hub launches theÌýDxD Hub Innovation & Enterprise Fellowship Programme (IFP).
Ìý
27th July 2023
Digital Health AcceleratorÌýLaunch Event is attended by over 100 attendees, with key stakeholders from the clusters, Ministry of Health, A*STAR leadership, DxD Hub advisors, and digital health practitioners.